Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981672 | 0.92 | ATM (0.40) | PTGDR2NR3C2MEN1KMT2A | |
| SCHEMBL981882 | 0.88 | PTGDR2 (0.40) | PTGDR2NR3C2MAPTMEN1KMT2A | |
| SCHEMBL984991 | 0.85 | PTGDR2 (0.38) | PTGDR2MEN1KMT2AALDH1A1 | |
| SCHEMBL981023 | 0.85 | ATM (0.40) | PTGDR2NR3C2MAPTMEN1KMT2A | |
| SCHEMBL980826 | 0.85 | CYP3A4 (0.38) | PTGDR2NR3C2L3MBTL1MAPTMEN1 | |
| SCHEMBL983370 | 0.84 | PTGDR2 (0.37) | PTGDR2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL983369 | 0.82 | MEN1 (0.39) | MAPTMEN1KMT2A | |
| SCHEMBL982927 | 0.82 | PTGDR2 (0.40) | PTGDR2MEN1KMT2A | |
| SCHEMBL985058 | 0.79 | SLC6A2 (0.53) | PTGDR2NR3C2L3MBTL1CMA1MEN1 | |
| SCHEMBL981169 | 0.79 | ATM (0.39) | PTGDR2NR3C2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257545-B1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMAN-LA ROCHE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | SLC6A3, MAOB, TPH2 | PTGDR2 373/4885NR3C2 406/4885L3MBTL1 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.